Evidence map›Paper›PMID 34046605›Full record

ArticleRSC medicinal chemistry2021

Towards a RIOK2 chemical probe: cellular potency improvement of a selective 2-(acylamino)pyridine series.

Christopher B Wang, Álvaro Lorente-Macías, Carrow Wells, Julie E Pickett, Alfredo Picado, William J Zuercher, Alison D Axtman

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Christopher B WangStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA alison.axtman@unc.edu.ORCID https://orcid.org/0000-0001-9648-1598
Álvaro Lorente-MacíasDepartamento de Química Farmacéutica y Orgánica, University of Granada Granada 18071 Spain.ORCID https://orcid.org/0000-0001-9510-714X
Carrow WellsStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA alison.axtman@unc.edu.ORCID https://orcid.org/0000-0003-4799-6792
Julie E PickettStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA alison.axtman@unc.edu.ORCID https://orcid.org/0000-0002-9535-8528
Alfredo PicadoStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA alison.axtman@unc.edu.
William J ZuercherStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA alison.axtman@unc.edu.
Alison D AxtmanStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA alison.axtman@unc.edu.ORCID https://orcid.org/0000-0003-4779-9932

Funding

Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
NIDDK NIH HHS U24 DK116204Wellcome Trust
6 · The paper itself

Abstract

RIOK2 is an understudied kinase associated with a variety of human cancers including non-small cell lung cancer and glioblastoma. No potent, selective, and cell-active chemical probe currently exists for RIOK2. Such a reagent would expedite re-search into the biological functions of RIOK2 and validate it as a therapeutic target. Herein, we describe the synthesis of naphthyl-pyridine based compounds that have improved cellular activity while maintaining selectivity for RIOK2. While our compounds do not represent RIOK2 chemical probes, they are the best available tool molecules to begin to characterize RIOK2 function

Identifiers

PMID34046605
PMCPMC8130602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.